Personalized venetoclax dosing for AML using AI
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a software tool that uses your genes and machine learning to find the best dose of venetoclax for you. It aims to improve treatment outcomes and reduce side effects for people with acute myeloid leukemia (AML).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with acute myeloid leukemia (AML)
- You are already planning to take venetoclax as part of your treatment
- Your blood counts are relatively stable before starting venetoclax: neutrophil count at least 1.0, white blood cell count at least 2.0, platelet count at least 50, and hemoglobin at least 90
- Your liver and kidney function are within acceptable ranges (no severe damage)
- You are not pregnant or breastfeeding, and you are willing to give written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the body processes venetoclax when it's given with azacitidine as a first treatment for acute myeloid leukemia (AML). It aims to understand how well the drug works and how the body handles it.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.